Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewSB 265610
说明： Potent CXCR2 antagonist
化学名： N-(2-Bromophenyl)-N'-(7-cyano-1H-benzotriazol-4-yl)urea
纯度： ≥98% (HPLC)
生物活性 for SB 265610
SB 265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). Inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.
许可信息
Sold for research purposes under agreement from GlaxoSmithKline
化合物库 for SB 265610
SB 265610 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. 了解 Tocris 化合物库的更多信息。
技术数据 for SB 265610
| 分子量 | 357.16 |
| 公式 | C14H9BrN6O |
| 储存 | Store at RT |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 211096-49-0 |
| PubChem ID | 9841667 |
| InChI Key | SEDUMQWZEOMXSO-UHFFFAOYSA-N |
| Smiles | O=C(NC3=C(Br)C=CC=C3)NC1=CC=C(C#N)C2=C1NN=N2 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for SB 265610
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 35.72 | 100 | |
| ethanol | 3.57 | 10 |
制备储备液 for SB 265610
以下数据基于产品分子量 357.16。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.8 mL | 14 mL | 28 mL |
| 5 mM | 0.56 mL | 2.8 mL | 5.6 mL |
| 10 mM | 0.28 mL | 1.4 mL | 2.8 mL |
| 50 mM | 0.06 mL | 0.28 mL | 0.56 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for SB 265610
参考文献 for SB 265610
参考文献是支持产品生物活性的出版物。
Auten et al (2001) Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J.Pharmacol.Exp.Ther. 299 90 PMID: 11561067
Milatovic et al (2003) Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 11 213 PMID: 12753603
If you know of a relevant reference for SB 265610, please let us know.
按产品操作查看相关产品
关键词: SB 265610, SB 265610 supplier, Potent, CXCR2, antagonists, Chemokine, Receptors, SB265610, GlaxoSmithKline, GSK, CXC, 2724, Tocris Bioscience
8 篇 SB 265610 的引用文献
引用文献是使用了 Tocris 产品的出版物。 SB 265610 的部分引用包括：
He et al (2018) Circadian Expression of Migratory Factors Establishes Lineage-Specific Signatures that Guide the Homing of Leukocyte Subsets to Tissues. Immunity 49 1175 PMID: 30527911
Ha et al (2014) A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. Br J Pharmacol 171 1551 PMID: 24354854
Bieren et al (2015) Immune Antibodies and Helminth Products Drive CXCR2-Dependent Macrophage-Myofibroblast Crosstalk to Promote Intestinal Repair. PLoS Pathog 11 e1004778 PMID: 25806513
Toh et al (2011) Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 9 e1001162 PMID: 21980263
Halpern et al (2011) Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett 308 91 PMID: 21601983
Burton et al (2011) Bone morphogenetic protein receptor II regulates pulmonary artery endothelial cell barrier function. Blood 117 333 PMID: 20724539
Jung et al (2016) CXCR2 Inhibition in Human Pluripotent Stem Cells Induces Predominant Differentiation to Mesoderm and Endoderm Through Repression of mTOR, β-Catenin, and hTERT Activities. Stem Cells Dev 25 1006 PMID: 27188501
Lavoie-Lamoureux et al (2010) IL-4 activates equine neutrophils and induces a mixed inflammatory cytokine expression profile with enhanced neutrophil chemotactic mediator release ex vivo. Am J Physiol Lung Cell Mol Physiol 299 L472 PMID: 20639353
您是否知道使用了 Tocris SB 265610 的优秀论文？ 请告知我们.
SB 265610 的评论
目前没有该产品的评论。 Be the first to review SB 265610 and earn rewards!
Have you used SB 265610?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.